Please ensure Javascript is enabled for purposes of website accessibility

Merck's Ebola Vaccine Approved for Use in Four African Countries

By Mark Prvulovic - Feb 14, 2020 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The World Health Organization is calling it a milestone in Ebola prevention.

Merck (MRK 0.83%) announced on Friday that four African countries had approved the use of the company's Ebola vaccine, Ervebo. The Democratic Republic of the Congo (DRC), Ghana, Zambia, and Burundi have all agreed to license the Ebola vaccine, with additional countries expected to approve the vaccine, as well, in the coming months.

Ervebo had already received approval from the U.S. Food and Drug Administration (FDA) back in December, while the European Commission granted the vaccine conditional marketing authorization just one-month prior in November. The use of the vaccine is limited to people who are at least 18 years old, and while Ervebo has demonstrated effectiveness in protecting patients from Ebola, the exact duration of how long this protection lasts is still uncertain.

A medical professional preparing a vaccine.

Image source: Getty Images.

"The approval of the Ebola vaccine by these countries is another milestone in the fight against this unforgiving disease. Africa has rallied to cement hard-fought progress to keep its people safe from Ebola," said World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus.

Further details

While the drug is manufactured by Merck, the WHO has played a crucial role in expediting the approval process for the vaccine. The healthcare organization certified Ervebo back in November in what was the fastest vaccine prequalification process in WHO history.

Ervebo has a 97.5% efficacy rate, according to the preliminary data, while those who are already infected with Ebola see a significant reduction in their chances of death after receiving the vaccine. Merck's stock is up less than 1% following the announcement.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.08 (0.83%) $0.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.